contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


optomed-oyj-optomeds-financial-reporting-in-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

A long segment has been released by Suther Health, and if you listen to it, Optomed and AI will definitely make a strong breakthrough. The train is moving fast, even though the stock price suggests otherwise:

Leana Wen, a member of Optomed’s board, interviewed CVS Health’s CMO at HLTH USA. The discussion focused on improving access to care, retail healthcare, and rapid diagnostic services — precisely the market that Optomed + AEYE are targeting in the USA. A positive sign: Optomed’s board has direct connections to U.S. healthcare giants (CVS/Aetna), where AI-powered retinal screenings can scale rapidly.                   linkedin.com              #hlthusa | HLTH USA    In a powerful conversation at #HLTHUSA 2025, Leana Wen M.D. M.Sc. sits down with Amy Compton-Phillips, MD, EVP & Chief Medical Officer at CVS Health, to explore one of healthcare’s most persistent challenges: making it easier for people to find,...

Both Aeye and Toku Clair will come to the Lumo camera. Aeye is much easier and faster to get. For Toku, we have to wait for Topcon to get approval first. Lumo Aeye will come first. A small addition : Here, we are first waiting for the Lumo 510k FDA approval to arrive. When that approval comes, it might very well happen that US customers start ordering the Lumo camera as capex. Of course, with the idea that when the Lumo Aeye approval comes, they will adopt it “at the push of a button”.

I agree. Now is the moment when a moat is being built in the United States. All efforts and resources should now be put into that. It has already been stated that the start has been slower than investors and the company itself expected. However, I am of the opinion that if and when Optomed survives alone and as the only one in this segment to the stage where several large chains start scaling the product, a huge competitive advantage and a moat will be created for Optomed. Once this type of device has been deployed, trained, and integrated into systems, it has a clear advantage even if competitors gradually start to emerge. In Finland, procurements go through general tendering, but still, the familiar and reliable device seems to win the tenders, and the scoring often favors the right device. And this tendering problem doesn’t even exist in the private markets of the United States; instead, a proven, familiar product is a relatively easy choice.

I am cautiously expecting it during 2026, based on the premise that Aurora could act as a ‘predicate’ device, allowing the utilization of the so-called bridging data principle. This would mean it’s sufficient to demonstrate that Lumo achieves essentially the same or better quality, and that its safety and effectiveness (efficacy) are at least on the same level. This would avoid extensive population studies. However, I cannot assess whether such a thing would be possible, but it is certainly within the realm of possibility.

Lumo was supposed to include Toku’s algorithm. At least, Himberg has said so. Cardiovascular disease diagnostics raises Optomed’s potential to a new level.

Question: Could Lumo Aeye get FDA approval by, for example, July 2026? In the last video, Himberg already stated that image data is being collected. My understanding is that he meant the Lumo Aeye combination (?). Images are taken, analyses are done, and papers are submitted for FDA processing, which takes a maximum of 90 days.

Optomed

Optomed PlcStock Exchange Release8 August 2024 at 9.05, HelsinkiOptomed's financial reporting in 2025Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and...

Optomed PlcStock Exchange Release8 August 2024 at 9.05, HelsinkiOptomed's financial reporting in 2025Optomed Plc will release its Financial Statement Bulletin, Half-Year Financial Report and Interim Reports in 2025 as follows:<ul><li>Financial Statement Bulletin for 1 January - 31 December 2024, 13 February 2025</li><li>Interim Report for 1 January - 31 March 2025, 6 May 2025</li><li>Half-Year Financial Report for 1 January - 30 June 2025, 7 August 2025</li><li>Interim Report for 1 January - 30 September 2025, 6 November 2025</li></ul>Annual Report 2024, which includes the company's financial statements, the report of the Board of Directors, the corporate governance statement and the remuneration report, will be published during the week starting on 24 February 2025 at the latest.Optomed's Annual General Meeting is planned to be held on 9 May 2025 in the Helsinki region, Finland. The Board of Directors will convene the meeting separately at a later date.A shareholder who requests a certain issue belonging to the General Meeting to be included on the agenda of the meeting, is asked to notify the Board of Directors in writing by post Optomed Plc, Yrttipellontie 1, FI-90230 Oulu, Finland no later than 13 March 2025.Optomed PlcFurther enquiriesSakari Knuutti, CFO, Optomed Plc, sakari.knuutti@optomed.comOptomed in BriefOptomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&amp;D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 55 international patents protecting the technology.www.optomed.com